These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30569694)

  • 1. Influence of pharmacist intervention, based on CMO model, to improve activation in HIV patients.
    Morillo-Verdugo R; Robustillo-Cortés MA; Manzano García M; Almeida-González CV
    Rev Esp Quimioter; 2019 Feb; 32(1):40-49. PubMed ID: 30569694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of the CMO methodology to the improvement of primary adherence to concomitant medication in people living with-HIV. The PRICMO Project.
    Morillo-Verdugo R; Vélez-Díaz-Pallarés M; Fernández-Pacheco García-Valdecasas M; Fernández-Espínola S; Sánchez-Rubio Ferrández J; Navarro-Ruiz A
    Farm Hosp; 2021 Jul; 45(5):247-252. PubMed ID: 34806584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact and acceptance of pharmacist-led interventions during HIV care in a third-level hospital in Spain using the Capacity-Motivation-Opportunity pharmaceutical care model: the IRAFE study.
    Cantillana-Suárez MG; Robustillo-Cortés MLA; Gutiérrez-Pizarraya A; Morillo-Verdugo R
    Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e157-e163. PubMed ID: 33627478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of CMO (capacity, motivation, and opportunity) methodology in pharmaceutical care to optimize the pharmacotherapy in older people living with HIV. DISPIMDINAC project.
    Sánchez-Yáñez E; Huertas-Fernández MJ; Robustillo-Cortes MA; Ramos-Guerrero R; Fernández-Espínola S; Diaz-Acedo R; Montero-Martin V; Morillo-Verdugo R
    Rev Esp Quimioter; 2023 Dec; 36(6):584-591. PubMed ID: 37724451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a Structured Pharmaceutical Care Intervention Versus Usual Care on Cardiovascular Risk in HIV Patients on Antiretroviral Therapy: INFAMERICA Study.
    Morillo-Verdugo R; Robustillo-Cortés MLA; Martín-Conde MT; Callejón-Callejón G; Cid-Silva P; Moriel-Sánchez C; Tortajada-Goitia B; Almeida-González CV
    Ann Pharmacother; 2018 Nov; 52(11):1098-1108. PubMed ID: 29808711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Process- and patient-reported outcomes of a multifaceted medication adherence intervention for hypertensive patients in secondary care.
    Hedegaard U; Hallas J; Ravn-Nielsen LV; Kjeldsen LJ
    Res Social Adm Pharm; 2016; 12(2):302-18. PubMed ID: 26088274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors and Evolution of Antiretroviral Therapy Adherence Among Perinatally HIV-Infected Adolescents in Brazil.
    Côté J; Delmas P; de Menezes Succi RC; Galano E; Auger P; Sylvain H; Colson S; Machado DM
    J Adolesc Health; 2016 Sep; 59(3):305-310. PubMed ID: 27320032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Patient Medication Adherence Questionnaire as a tool for self-reported adherence assessment in HIV-infected patients on antiretroviral regimens.
    Duong M; Piroth L; Grappin M; Forte F; Peytavin G; Buisson M; Chavanet P; Portier H
    HIV Clin Trials; 2001; 2(2):128-35. PubMed ID: 11590521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to Antiretroviral Therapy in Turkey: Results from the ACTHIV-IST Study Group.
    Yildiz Sevgi D; Gunduz A; Altuntas Aydin O; Mete B; Sargin F; Kumbasar Karaosmanoglu H; Uzun N; Yemisen M; Dokmetas I; Tabak F
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1192-1198. PubMed ID: 28854809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving adherence and clinical outcomes through an HIV pharmacist's interventions.
    Ma A; Chen DM; Chau FM; Saberi P
    AIDS Care; 2010 Oct; 22(10):1189-94. PubMed ID: 20640958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of an adherence program to antiretroviral treatment on virologic response in a cohort of multitreated and poorly adherent HIV-infected patients in Spain.
    Navarro J; Pérez M; Curran A; Burgos J; Feijoo M; Torrella A; Caballero E; Ocaña I; Ribera E; Crespo M; Falcó V
    AIDS Patient Care STDS; 2014 Oct; 28(10):537-42. PubMed ID: 25111167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with adherence to antiretroviral therapy among HIV/AIDS patients in rural China.
    Wang X; Wu Z
    AIDS; 2007 Dec; 21 Suppl 8():S149-55. PubMed ID: 18172384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caregiver-reported antiretroviral therapy non-adherence during the first week and after a month of treatment initiation among children diagnosed with HIV in Ethiopia.
    Biru M; Jerene D; Lundqvist P; Molla M; Abebe W; Hallström I
    AIDS Care; 2017 Apr; 29(4):436-440. PubMed ID: 27842440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An interdisciplinary HIV-adherence program combining motivational interviewing and electronic antiretroviral drug monitoring.
    Krummenacher I; Cavassini M; Bugnon O; Schneider MP
    AIDS Care; 2011 May; 23(5):550-61. PubMed ID: 21271406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Socioeconomic factors explain suboptimal adherence to antiretroviral therapy among HIV-infected Australian adults with viral suppression.
    Siefried KJ; Mao L; Kerr S; Cysique LA; Gates TM; McAllister J; Maynard A; de Wit J; Carr A;
    PLoS One; 2017; 12(4):e0174613. PubMed ID: 28369066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
    Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G;
    Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory Bowel Disease Pharmacist Adherence Counseling Improves Medication Adherence in Crohn's Disease and Ulcerative Colitis.
    Tiao DK; Chan W; Jeganathan J; Chan JT; Perry J; Selinger CP; Leong RW
    Inflamm Bowel Dis; 2017 Aug; 23(8):1257-1261. PubMed ID: 28719539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China.
    Chen J; Zhang M; Shang M; Yang W; Wang Z; Shang H
    BMC Infect Dis; 2018 Nov; 18(1):571. PubMed ID: 30442114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral adherence program in HIV patients: a feasibility study in the Swiss HIV Cohort Study.
    Krummenacher I; Cavassini M; Bugnon O; Spirig R; Schneider MP;
    Pharm World Sci; 2010 Dec; 32(6):776-86. PubMed ID: 20862544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.